Darunavir/ritonavir and efavirenz exert differential effects on MRP1 transporter expression and function in healthy volunteers

Antiviral Therapy

Volumn 15, Issue 2, 2010, Pages 275-279

  Lee, Lawrence S ^a,b,c   Soon, Gaik H ^a   Shen, Ping ^b   Yong, Eu Leong ^b   Flexner, Charles ^c   Pham, Paul ^c  

^a NATIONAL HEALTHCARE GROUP   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETOACETIC ACID; ANTIBODY; CARBOXYFLUORESCEIN; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; FLUORESCEIN ISOTHIOCYANATE; MULTIDRUG RESISTANCE PROTEIN 1; PHYCOERYTHRIN; PROBENECID; RITONAVIR; VERLUKAST;

ABDOMINAL PAIN; ADD ON THERAPY; ADULT; AGED; ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; ENZYME BLOOD LEVEL; FEMALE; FEVER; FLOW CYTOMETRY; FLUORESCENCE; GEOMETRY; HUMAN; HUMAN CELL; MACULOPAPULAR RASH; MALE; NEUROLOGIC DISEASE; PAPULAR RASH; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIDE EFFECT; VOLUNTEER; VOMITING;

ADULT; AGED; ANTI-HIV AGENTS; BENZOXAZINES; DRUG THERAPY, COMBINATION; FEMALE; GENE EXPRESSION REGULATION; HIV SERONEGATIVITY; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; SULFONAMIDES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77950657842     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1505     Document Type: Article

References (17)

1. Owen A, Khoo SH. Intracellular pharmacokinetics of antiretroviral agents. J HIV Ther 2004; 9:97-101.
2. Turriziani O, Gianotti N, Falasca F, et al. Expression levels of MDR1. MRP1, MRP4, and MRP5 in peripheral blood mononuclear cells from HIV infected patients failing antiretroviral therapy. J Med Virol 2008; 80:766-771. (Pubitemid 351500021)
3. Bousquet L, Pruvost A, Didier N, Farinotti R, Mabondzo A, Emtricitabine: Inhibitor and subsrtare of multidrug resistance associated protein. Eur J Pharm Sci 2008; 35:247-256.
4. Janneh O, Jones E, Chandler B, Owen A, Khoo SH. Inhibition of P-glycoprotein and mulridrug resisrance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocyres. J Antimicrob Chemother 2007; 60:987-993. (Pubitemid 47617744)
5. Janneh O, Owen A, Chandler B, et al. Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS 2005; 19:2097-2102. (Pubitemid 41668997)
6. Jorajuria S, Dereuddre-Bosquet N, Becher F, et al. ATP binding cassette mulridrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages. Antivir Ther 2004; 9:519-528. (Pubitemid 39150209)
7. Meaden ER, Hoggard PG. Newton P, et al. P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals. J Antimicrob Chemother 2002; 50:583-588. (Pubitemid 35214800)
8. Weiss J, Theile D, Ketabi-Kiyanvash N, Lindenmaier H, Haefeli WE. Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors. Drug Metab Dispos 2007; 35:340-344. (Pubitemid 46333919)
9. Meaden ER, Hoggard PG, Khoo SH, Back DJ. Determination of P-gp and MRP1 expression and function in peripheral blood mononuclear cells in vivo. J Immunol Methods 2002; 262:159-165. (Pubitemid 34450740)
10. Lucia MB, Savarino A, Straface E, et al. Role of lymphocyte mulridrug resistance protein 1 in HIV infection: expression, function, and consequences of inhibition. J Acquir Immune Defic Syndr 2005; 40:257-266. (Pubitemid 41533064)
11. Lucia MB, Rutella S, Leone G, Vella S, Cauda R. HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART. J Acquir Immune Defic Syndr 2001; 27:321-330. (Pubitemid 32729077)
12. + cells. Eur J Haematol 2003; 71:119-123.
13. Dogan AL, Legrand O, Faussat AM, Perrot JY, Marie JP. Evaluation and comparison of MRP1 activity with three fluorescent dyes and three modulators in leukemic cell lines. Leuk Res 2004; 28:619-622. (Pubitemid 38543199)
14. Matsson P, Pedersen JM, Norinder U, Bergstrom CA, Artursson P. Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm Res 2009; 26:1816-1831.
15. Enomoto A, Takeda M, Shimoda M, et al. Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors. J Pharmacol Exp Ther 2002; 301:797-802. (Pubitemid 34595067)
16. Bousquet L, Pruvost A, Guyot AC, Farinotti R, Mabondzo A. Combination of tenofovir and emtricitabine plus efavirenz: in vitro modulation of ABC transporter and intracellular drug accumulation. Antimicrob Agents Chemother 2009; 53:896-902.
17. Colombo S, Telenti A, Buclin T, et al. Are plasma levels valid surrogates for cellular concentrations of antiretroviral drugs in HIV-infected patients? Ther Drug Monit 2006; 28:332-338. (Pubitemid 44314919)